Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00002481
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Bone marrow transplantation may allow doctors to give higher doses of radiation therapy and chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of high-dose etoposide and cyclophosphamide plus total-body irradiation followed by bone marrow transplantation in treating pati... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/17/2013
Locations: St. Luke's Medical Center, Milwaukee, Wisconsin
Conditions: Lymphoma
Register for Updates
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00324831
Suspended
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Colony-stimulating factors, such as GM-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/17/2013
Locations: Tower Cancer Research Foundation, Beverly Hills, California +1 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
NCT00392886
Unknown
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A bone marrow or peripheral stem cell transplant using stem cells from the patient may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed. PURPOSE: This phase III trial is studying how well giving combination chemotherapy with or with... Read More
Gender:
ALL
Ages:
10 years and below
Trial Updated:
12/17/2013
Locations: Phoenix Children's Hospital Outpatient Center, Phoenix, Arizona +36 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Chemotherapy, Surgery, Radiation Therapy and Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Primary CNS Germ Cell Tumors
NCT00025324
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation or bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase II trial to study the effectiveness of chemotherapy, surgery, radiation therapy, and bone marrow or peripheral stem cell transplantation in... Read More
Gender:
ALL
Ages:
All
Trial Updated:
12/17/2013
Locations: Children's Hospital Los Angeles, Los Angeles, California +3 locations
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Docetaxel in Breast Cancer
NCT00312208
Completed
Primary objective : * To compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to doxorubicin and cyclophosphamide followed by docetaxel in operable adjuvant breast cancer HER2neu negative patients with positive axillary lymph nodes. Secondary objectives : * To compare toxicity and quality of life between the 2 above-mentioned arms. * To evaluate pathologic and molecular markers for predicting efficacy.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
12/04/2013
Locations: Sanofi-Aventis, Bridgewater, New Jersey +36 locations
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00005959
Unknown
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one chemotherapy drug with rituximab may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have intermedi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: Montgomery Cancer Center, Montgomery, Alabama +26 locations
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005960
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: Wilshire Oncology Medical Group, Inc., Los Angeles, California +5 locations
Conditions: Pain, Prostate Cancer
Register for Updates
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
NCT00003490
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. GM-CSF may make cancer cells more sensitive to the effects of chemotherapy. Combining more than one drug with GM-CSF may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, consisting of cyclophosphamide plus vincristine, following GM-CSF in treating patients with multiple myeloma that has not responded to previous treatment.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/03/2013
Locations: Cleveland Clinic Cancer Center, Cleveland, Ohio
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
NCT00017290
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Vaccines may make the body build an immune response to kill cancer cells. It is not yet known which regimen of chemotherapy combined with vaccine therapy is more effective for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to determine the effectiveness of combination chemotherapy followed by vaccine therapy plus sargramostim in treating patients who have stage I... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: SuperGen, Incorporated, Dublin, California +23 locations
Conditions: Lymphoma
Register for Updates
Biological Therapy in Treating Patients With Glioblastoma Multiforme
NCT00003185
Completed
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase II trial to study the effectiveness of biological therapy in treating patients with glioblastoma multiforme.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)
NCT00750815
Completed
Cyclophosphamide is a chemotherapy agent with known activity in myeloma. The new regimen that we will test in this study is called CVDD and contains Cyclophosphamide with Bortezomib (VELCADE), Pegylated Liposomal Doxorubicin (DOXIL®, PLD), and Dexamethasone (VDD). The purpose of this study is to determine if the addition of another type of chemotherapy agent, Cyclophosphamide, to the regimen VDD (CVDD) is well tolerated and improves response rates in myeloma. We will also find the highest safe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2013
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Multiple Myeloma
Register for Updates
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
NCT00121134
Completed
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of these drugs * See how easy or difficult it is to be treated with them * Monitor for any signs of recurrent cancer * Look at blood markers that might indicate how the treatment is working
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/26/2013
Locations: University of California, San Francisco, San Francisco, California +4 locations
Conditions: Breast Cancer
Register for Updates